Brain amyloidoses comprise a heterogeneous group of diseases that vary in clinical expression and the composition and distribution of insoluble amyloid fibrils. We believe that all types of cerebral amyloids involve altered degradation of an amyloid precursor protein, and that deposition occurs in patients who are genetically or otherwise defective in degrading these molecules. We put forward a tripartite division of the elements central to the issue of pathogenesis: the inherent chemical amyloidogenic potential of the precursor protein; the possibility of aberrant protein metabolism and/or genetic variants, and the existence of disease microenvironmental tissue factors that may facilitate the conversion of precursor proteins into their insoluble amyloid products. Recently we have shown that the amyloid fibrils of sporadic cerebral amyloid angiopathy and an autosomal dominant form of familial amyloid angiopathy in patients of Dutch origin (also designated Hereditary Cerebral Hemorrhage with Amyloidosis of Dutch Type) are similar to Alzheimer Disease amyloid beta-protein (Abeta). These findings indicate that Abeta deposition disorders form a spectrum of overlapping clinico-pathological conditions which range from patients with predominant vascular involvement to patients having a combination of vascular and parenchyma involvement in varying proportions, manifested clinically by stroke and dementia, respectively. We have also found that these disorders exhibit varying neuritic plaque-like structures, or """"""""preamyloid lesions"""""""", suggesting that they represent an early stage of beta-protein deposition. Similar amyloid deposits are often encountered in a significant percent of neurologically asymptomatic aged individuals; hence it is important to clarify their relationship. We propose: 1) the biochemical and immunohistochemical analysis of preamyloid lesions obtained from Dutch patients with HCHWA and familial and sporadic forms of AD. 2) the characterization of amyloid protein and other components from familial and sporadic forms of AD. 3) performing similar studies in transgenic mice. This study is relevant for understanding the basic etiopathogenetic mechanisms associated with amyloid deposition in aging, amyloid angiopathy, and Alzheimer's Disease; it may be useful for diagnostic purposes at a pathological and clinical level and for therapeutic intervention.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Unknown (R35)
Project #
5R35AG010953-02
Application #
3768635
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
1993
Total Cost
Indirect Cost
Name
New York University
Department
Type
DUNS #
004514360
City
New York
State
NY
Country
United States
Zip Code
10012
Baumann, M H; Kallijarvi, J; Lankinen, H et al. (2000) Apolipoprotein E includes a binding site which is recognized by several amyloidogenic polypeptides. Biochem J 349:77-84
Vidal, R; Revesz, T; Rostagno, A et al. (2000) A decamer duplication in the 3' region of the BRI gene originates an amyloid peptide that is associated with dementia in a Danish kindred. Proc Natl Acad Sci U S A 97:4920-5
Mead, S; James-Galton, M; Revesz, T et al. (2000) Familial British dementia with amyloid angiopathy: early clinical, neuropsychological and imaging findings. Brain 123 ( Pt 5):975-91
Poduslo, J F; Curran, G L; Kumar, A et al. (1999) Beta-sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma. J Neurobiol 39:371-82
Rostagno, A; Vidal, R; Kaplan, B et al. (1999) pH-dependent fibrillogenesis of a VkappaIII Bence Jones protein. Br J Haematol 107:835-43
Koudinov, A R; Berezov, T T; Koudinova, N V (1998) Alzheimer's amyloid beta and lipid metabolism: a missing link? FASEB J 12:1097-9
Crawford, F; Soto, C; Suo, Z et al. (1998) Alzheimer's beta-amyloid vasoactivity: identification of a novel beta-amyloid conformational intermediate. FEBS Lett 436:445-8
Wisniewski, T; Dowjat, W K; Buxbaum, J D et al. (1998) A novel Polish presenilin-1 mutation (P117L) is associated with familial Alzheimer's disease and leads to death as early as the age of 28 years. Neuroreport 9:217-21
Soto, C; Sigurdsson, E M; Morelli, L et al. (1998) Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med 4:822-6
Permanne, B; Perez, C; Soto, C et al. (1997) Detection of apolipoprotein E/dimeric soluble amyloid beta complexes in Alzheimer's disease brain supernatants. Biochem Biophys Res Commun 240:715-20

Showing the most recent 10 out of 50 publications